Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL versus GYNE SULF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL versus GYNE SULF.
GANTANOL vs GYNE-SULF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydropteroate synthase, preventing folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate production. The combination produces sequential blockade of folate metabolism, leading to bactericidal activity.
GYNE-SULF (sulfisoxazole) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth.
800 mg orally every 12 hours for 5-7 days.
Intravaginal: One full applicator (approximately 5 g of 2% cream, containing 100 mg sulfanilamide) inserted intravaginally once daily (at bedtime) for 7-10 days. Alternatively, one vaginal suppository (containing 250 mg sulfanilamide) inserted intravaginally twice daily (morning and bedtime) for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults; prolonged in renal impairment (up to 24-36 hours in CrCl <30 mL/min).
Terminal elimination half-life: 10-12 hours (normal renal function). In renal impairment (CrCl <30 mL/min): up to 24-48 hours.
Renal: 70% as unchanged drug; hepatic metabolism: 20% (glucuronidation); fecal: 10%.
Renal: 80% (unchanged). Biliary/fecal: 15% as metabolites. Metabolized by reduction and acetylation; parent and metabolites undergo glomerular filtration and active tubular secretion.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic